234 related articles for article (PubMed ID: 37433716)
1. Combination oncolytic virus, radiation therapy, and immune checkpoint inhibitor treatment in anti-PD-1-refractory cancer.
Jhawar SR; Wang SJ; Thandoni A; Bommareddy PK; Newman JH; Marzo AL; Kuzel TM; Gupta V; Reiser J; Daniels P; Schiff D; Mitchell D; LeBoeuf NR; Simmons C; Goyal S; Lasfar A; Guevara-Patino JA; Haffty BG; Kaufman HL; Silk AW; Zloza A; Giurini EF
J Immunother Cancer; 2023 Jul; 11(7):. PubMed ID: 37433716
[TBL] [Abstract][Full Text] [Related]
2. Oncolytic virus expressing PD-1 inhibitors activates a collaborative intratumoral immune response to control tumor and synergizes with CTLA-4 or TIM-3 blockade.
Ju F; Luo Y; Lin C; Jia X; Xu Z; Tian R; Lin Y; Zhao M; Chang Y; Huang X; Li S; Ren W; Qin Y; Yu M; Jia J; Han J; Luo W; Zhang J; Fu G; Ye X; Huang C; Xia N
J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35688558
[TBL] [Abstract][Full Text] [Related]
3. An engineered oncolytic vaccinia virus encoding a single-chain variable fragment against TIGIT induces effective antitumor immunity and synergizes with PD-1 or LAG-3 blockade.
Zuo S; Wei M; Xu T; Kong L; He B; Wang S; Wang S; Wu J; Dong J; Wei J
J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34949694
[TBL] [Abstract][Full Text] [Related]
4. Surface engineering of oncolytic adenovirus for a combination of immune checkpoint blockade and virotherapy.
Lv P; Chen X; Fu S; Ren E; Liu C; Liu X; Jiang L; Zeng Y; Wang X; Liu G
Biomater Sci; 2021 Nov; 9(22):7392-7401. PubMed ID: 34751685
[TBL] [Abstract][Full Text] [Related]
5. Adenovirus Encoding Tumor Necrosis Factor Alpha and Interleukin 2 Induces a Tertiary Lymphoid Structure Signature in Immune Checkpoint Inhibitor Refractory Head and Neck Cancer.
Clubb JHA; Kudling TV; Heiniö C; Basnet S; Pakola S; Cervera Carrascón V; Santos JM; Quixabeira DCA; Havunen R; Sorsa S; Zheng V; Salo T; Bäck L; Aro K; Tulokas S; Loimu V; Hemminki A
Front Immunol; 2022; 13():794251. PubMed ID: 35355980
[TBL] [Abstract][Full Text] [Related]
6. Combination of radiation therapy, bempegaldesleukin, and checkpoint blockade eradicates advanced solid tumors and metastases in mice.
Pieper AA; Rakhmilevich AL; Spiegelman DV; Patel RB; Birstler J; Jin WJ; Carlson PM; Charych DH; Hank JA; Erbe AK; Overwijk WW; Morris ZS; Sondel PM
J Immunother Cancer; 2021 Jun; 9(6):. PubMed ID: 34172518
[TBL] [Abstract][Full Text] [Related]
7. Combining BRAF inhibition with oncolytic herpes simplex virus enhances the immune-mediated antitumor therapy of BRAF-mutant thyroid cancer.
Crespo-Rodriguez E; Bergerhoff K; Bozhanova G; Foo S; Patin EC; Whittock H; Buus R; Haider S; Muirhead G; Thway K; Newbold K; Coffin RS; Vile RG; Kim D; McLaughlin M; Melcher AA; Harrington KJ; Pedersen M
J Immunother Cancer; 2020 Aug; 8(2):. PubMed ID: 32759235
[TBL] [Abstract][Full Text] [Related]
8. Development of a new fusion-enhanced oncolytic immunotherapy platform based on herpes simplex virus type 1.
Thomas S; Kuncheria L; Roulstone V; Kyula JN; Mansfield D; Bommareddy PK; Smith H; Kaufman HL; Harrington KJ; Coffin RS
J Immunother Cancer; 2019 Aug; 7(1):214. PubMed ID: 31399043
[TBL] [Abstract][Full Text] [Related]
9. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
[TBL] [Abstract][Full Text] [Related]
10. Combination therapy with oncolytic viruses and immune checkpoint inhibitors.
Chiu M; Armstrong EJL; Jennings V; Foo S; Crespo-Rodriguez E; Bozhanova G; Patin EC; McLaughlin M; Mansfield D; Baker G; Grove L; Pedersen M; Kyula J; Roulstone V; Wilkins A; McDonald F; Harrington K; Melcher A
Expert Opin Biol Ther; 2020 Jun; 20(6):635-652. PubMed ID: 32067509
[No Abstract] [Full Text] [Related]
11. Optimal timing of PD-1 blockade in combination with oncolytic virus therapy.
Nguyen HM; Bommareddy PK; Silk AW; Saha D
Semin Cancer Biol; 2022 Nov; 86(Pt 3):971-980. PubMed ID: 34033895
[TBL] [Abstract][Full Text] [Related]
12. Telomerase-specific oncolytic immunotherapy for promoting efficacy of PD-1 blockade in osteosarcoma.
Mochizuki Y; Tazawa H; Demiya K; Kure M; Kondo H; Komatsubara T; Sugiu K; Hasei J; Yoshida A; Kunisada T; Urata Y; Kagawa S; Ozaki T; Fujiwara T
Cancer Immunol Immunother; 2021 May; 70(5):1405-1417. PubMed ID: 33151368
[TBL] [Abstract][Full Text] [Related]
13. Combination of vasculature targeting, hypofractionated radiotherapy, and immune checkpoint inhibitor elicits potent antitumor immune response and blocks tumor progression.
Pierini S; Mishra A; Perales-Linares R; Uribe-Herranz M; Beghi S; Giglio A; Pustylnikov S; Costabile F; Rafail S; Amici A; Facciponte JG; Koumenis C; Facciabene A
J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33563772
[TBL] [Abstract][Full Text] [Related]
14. Oncolytic viruses combined with immune checkpoint therapy for colorectal cancer is a promising treatment option.
Ren Y; Miao JM; Wang YY; Fan Z; Kong XB; Yang L; Cheng G
Front Immunol; 2022; 13():961796. PubMed ID: 35911673
[TBL] [Abstract][Full Text] [Related]
15. Natural killer T cell immunotherapy combined with IL-15-expressing oncolytic virotherapy and PD-1 blockade mediates pancreatic tumor regression.
Nelson A; Gebremeskel S; Lichty BD; Johnston B
J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35246474
[TBL] [Abstract][Full Text] [Related]
16. Dual but not single PD-1 or TIM-3 blockade enhances oncolytic virotherapy in refractory lung cancer.
Sun F; Guo ZS; Gregory AD; Shapiro SD; Xiao G; Qu Z
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32461344
[TBL] [Abstract][Full Text] [Related]
17. Oncolytic poxvirus CF33-hNIS-ΔF14.5 favorably modulates tumor immune microenvironment and works synergistically with anti-PD-L1 antibody in a triple-negative breast cancer model.
Chaurasiya S; Yang A; Kang S; Lu J; Kim SI; Park AK; Sivanandam V; Zhang Z; Woo Y; Warner SG; Fong Y
Oncoimmunology; 2020; 9(1):1729300. PubMed ID: 32158622
[TBL] [Abstract][Full Text] [Related]
18. A dual-functional oncolytic adenovirus ZD55-aPD-L1 scFv armed with PD-L1 inhibitor potentiates its antitumor activity.
Mei S; Peng S; Vong EG; Zhan J
Int Immunopharmacol; 2024 Feb; 128():111579. PubMed ID: 38278066
[TBL] [Abstract][Full Text] [Related]
19. Superagonist IL-15-Armed Oncolytic Virus Elicits Potent Antitumor Immunity and Therapy That Are Enhanced with PD-1 Blockade.
Kowalsky SJ; Liu Z; Feist M; Berkey SE; Ma C; Ravindranathan R; Dai E; Roy EJ; Guo ZS; Bartlett DL
Mol Ther; 2018 Oct; 26(10):2476-2486. PubMed ID: 30064894
[TBL] [Abstract][Full Text] [Related]
20. Development of a Syrian hamster anti-PD-L1 monoclonal antibody enables oncolytic adenoviral immunotherapy modelling in an immunocompetent virus replication permissive setting.
Clubb JHA; Kudling TV; Girych M; Haybout L; Pakola S; Hamdan F; Cervera-Carrascon V; Hemmes A; Grönberg-Vähä-Koskela S; Santos JM; Quixabeira DCA; Basnet S; Heiniö C; Arias V; Jirovec E; Kaptan S; Havunen R; Sorsa S; Erikat A; Schwartz J; Anttila M; Aro K; Viitala T; Vattulainen I; Cerullo V; Kanerva A; Hemminki A
Front Immunol; 2023; 14():1060540. PubMed ID: 36817448
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
